Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
52W High
$9.47
52W Low
$1.27
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.34
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.56
EV/Revenue (<3 favorable)
1.88
P/S (TTM) (<3 favorable)
3.26
P/B (<3 favorable)
0.83
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
31.48%
Institutions (25–75% balanced)
11.44%
Shares Outstanding
3,203,300
Float
2,467,600
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
2,174,000
Gross Profit (TTM)
2,231,000
EPS (TTM)
-0.69
Profit Margin (>10% good)
-0.90%
Operating Margin (TTM) (higher better)
-17.98%
ROE (TTM) (>15% strong)
-0.22%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.14
Momentum
Bearish momentumValue
-0.0608
Previous
-0.0672
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025